Screener
Syndax Pharmaceuticals SNDX Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Long-term liabilities: | ||
| Royalty interest financing liability, less current portion | 343,965 | 343,909 |
| Right-of-use liability, less current portion | 907 | 1,051 |
| Total long-term liabilities | 344,872 | 344,960 |
| Total liabilities | 431,046 | 465,076 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025 | — | — |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total non-current liabilities?
- Syndax Pharmaceuticals (SNDX) reported total non-current liabilities of $344.87M in Q1 2026.
- How has Syndax Pharmaceuticals's total non-current liabilities changed year-over-year?
- Syndax Pharmaceuticals's total non-current liabilities increased by 4.2% year-over-year, from $331.1M to $344.87M.
- What is the long-term trend for Syndax Pharmaceuticals's total non-current liabilities?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total non-current liabilities has grown at a 63.5% compound annual growth rate (CAGR), from $29.55M to $344.96M.
- What does total non-current liabilities mean?
- The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.
Ask your AI about Syndax Pharmaceuticals's total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude